Nervous Disorder TRIZ Cases

Single Sox2 factor reprograms somatic cells into multipotent induced neural stem cells, eliminating complex induction factors and tumorigenicity risks.

Combines a respiratory stimulant with an opioid receptor agonist to maintain analgesic efficacy.

Pyrimidine derivatives traverse the blood-brain barrier to inhibit LRRK2, addressing limited therapeutic options for neurodegenerative diseases.

Lipidated PrRP analogs improve insulin signaling and reduce Tau hyperphosphorylation to slow disease progression in Alzheimer's models.

Combining 2-aminoethanesulfonic acid with calcium channel blockers or angiotensin receptor blockers in a single preparation.

Prasinezumab neutralizes toxic alpha-synuclein aggregates, addressing root causes of neuronal death rather than managing symptoms.

Selective estrogen receptor beta ligands provide long-term neuroprotection without the cancer risks associated with alpha ligand treatments.

A fusion peptide comprising dhFas-1 and RGD motifs inhibits synoviocyte adhesion and migration.

Developing a novel crystalline S-apomorphine hydrochloride hydrate salt with defined water content resolves poor solubility and instability of the free base.

Cyclic peptides bind melanocortin receptors to modulate energy homeostasis and food intake.

Single-chain variable fragment antibodies expressed in neurons target toxic amyloid-beta oligomers.

Cannabigerol provides antidepressant effects through endocannabinoid system interaction.

Chimeric antibodies bind (+) methamphetamine in the bloodstream, blocking brain entry and reducing reinforcing effects that drive addiction relapse.

Optimizing pH and ionic strength resolves the trade-off between storage modulus and gelation time, enabling rapid formation of stiff peptide gels.

Targeting the RRM-1 domain of TDP-43 reduces nuclear protein levels and NF-kB activation, addressing limited therapeutic options for ALS.

Bispecific antigen binding proteins bind human CGRP and PAC1 receptors to modulate signaling cascades.

A collagen-cellulose composite material mimics natural tissue structures for medical device testing.

Selective extraction removes caffeine while retaining beneficial compounds to improve glucose balance.

Merging omega-3s and choline addresses inconsistent single-nutrient results by targeting multiple cognitive decline risk factors.

Implanted drug depot releases bupivacaine and clonidine locally to avoid systemic opioid side effects.

Administering a cannabis extract with at least 5.4% limonene addresses complex sleep disorder needs.

Single-chain fusion protein with galanin targeting moiety and non-cytotoxic protease cleaves exocytic fusion apparatus proteins.

Small organic molecules inhibit bone morphogenetic proteins to resolve insufficient demyelination inhibition and remyelination promotion in multiple sclerosis.

Biaryl compounds inhibit Bruton's tyrosine kinase by applying local quality and parameter changes to resolve selectivity versus complexity trade-offs.

Acid buffering adjusts aqueous solution pH to 2.5-4.5, enhancing solubility and masking bitter taste of compound I.

Recombinant neurotrophic viral vectors deliver transgenes to ependymal cells via intraventricular injection.

Genotyping specific single nucleotide polymorphisms identifies predicted responders for glatiramer acetate therapy.

Boron-containing compounds inhibit arginase enzymes to restore cellular nitric oxide levels, addressing inadequate treatments for pulmonary hypertension.

Viral vectors carrying composite enhancers deliver cell type-specific transgenes to neocortical L4 and L5 IT neurons, bypassing complex germline crosses.

Genetic testing identifies ABCB1 variants to guide antidepressant selection and dosage adjustments.

Standardized cannabidiol dosing accelerates titration to maintenance levels, reducing breakthrough seizures and improving adherence.

Fibroblast scaffolds enable structured delivery of contractile cells to reverse maladaptive remodeling.

Reparixin targets the CXCL8/CXCR1 axis to treat refractory seizures and prevent neurological damage.

Implanted reservoir delivers stem cells directly into the human ventricular system, bypassing lung trapping and cerebral lesions caused by conventional routes.

Substituted xanthine compounds inhibit TRPC5 ion flux to address the lack of specific modulators for treating neuropsychiatric and seizure disorders.

Phosphorus-substituted quinoxaline piperidine compounds target the ORL-1 receptor to reduce side effects associated with traditional opioid analgesics.

Increasing p21 activity prevents neuronal apoptosis and halts neurodegeneration progression caused by WFS1 deficiency.

Dorsomorphin and imidazole benzamide block BMP and Activin/Nodal signaling to drive stem cell neural differentiation.

Controlled seeding and cooling separate interfering Z-isomers to boost entacapone yield.

A pharmaceutical hemostatic liquid foam uses native albumin to generate stable gas bubbles for immediate surgical application.

Antibodies sequester PCSK9 via extraction and parameter changes, preserving LDLR levels for hypercholesterolemia treatment.

Tyr-Leu-Gly tripeptide promotes brain-derived neurotrophic factor expression to enhance cognitive function.

Segmented rigid air conduits in a breath-powered inhaler ensure consistent dosing and high deagglomeration efficiency without propellants.

Antibodies targeting the IL-6/IL-6R complex resolve neutralization efficacy versus concentration trade-offs by blocking gp130 interaction at lower doses.

Targeting pathogenic Tau oligomers with specific antibodies resolves the contradiction between symptomatic relief and definitive early diagnosis of tauopathies.

Segmented peptides overcome blood-brain barrier limitations to promote axonal growth and improve memory formation.